^
    4d
    A Randomized Phase II Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, University of Chicago
    New P2 trial
    |
    carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    7d
    A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (clinicaltrials.gov)
    P2, N=195, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    8d
    RELATIVITY-106: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (clinicaltrials.gov)
    P1/2, N=83, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=162 --> 83 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • relatlimab (BMS-986016)
    11d
    GIANT: Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (clinicaltrials.gov)
    P2, N=92, Recruiting, Duke University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    11d
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov)
    P2, N=20, Completed, Dan Zandberg | Active, not recruiting --> Completed
    Trial completion
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    11d
    RELATIVITY-073: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (clinicaltrials.gov)
    P2, N=266, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    12d
    Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma (clinicaltrials.gov)
    P2, N=90, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jul 2027 --> Nov 2028 | Trial primary completion date: Jul 2027 --> Nov 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    LDH elevation
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    13d
    CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. (PubMed, Circulation)
    The major risk factor for ICI myocarditis is the use of combination ICI treatment, especially when relatlimab, a novel anti-LAG-3 (lymphocyte-activation gene 3) antibody, is combined with anti-PD-1 (programmed cell death protein 1) therapy...Treatment with anti-CXCR6 antibody prevented premature lethality, attenuated arrhythmias, and reduced the histological severity of myocarditis, demonstrating that CXCR6+ T cells are necessary for disease pathogenesis. Our findings suggest that ICI myocarditis is driven by an expansion of CXCR6+ T cells and identifies CXCR6 as a putative therapeutic target for this highly morbid condition.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD4 (CD4 Molecule) • GZMB (Granzyme B) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • GZMK (Granzyme K) • CXCL16 (C-X-C Motif Chemokine Ligand 16)
    |
    relatlimab (BMS-986016)
    15d
    Study of ZGGS15 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=22, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Jun 2025 | Trial primary completion date: Aug 2026 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    ZGGS15
    29d
    R3767-ONC-2011: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
    P3, N=1546, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    1m
    KeyForm-010: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab/pembrolizumab (MK-4280A)
    1m
    Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Jun 2030 | Trial primary completion date: Dec 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)